Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
INNV > SEC Filings for INNV > Form 8-K on 11-Sep-2013All Recent SEC Filings

Show all filings for INNOVUS PHARMACEUTICALS, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for INNOVUS PHARMACEUTICALS, INC.


11-Sep-2013

Change in Directors or Principal Officers, Other Events, Financial


Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers

Morgan Brown, Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals, Inc. (the "Company"), announced his resignation from the Company, effective September 22, 2013. Mr. Brown's resignation is not related to any disagreement with the Company.



Item 8.01 Other Events

On September 9, 2013, the Company announced that it had entered into an exclusive license and distribution agreement with Ovation Pharma SARL ("Ovation"), pursuant to which Ovation will market the Company's CIRCUMserum™ product for the treatment of reduced penile sensitivity in Morocco.

Pursuant to the agreement, Ovation will pay the Company up to $11.25 million upon and subject to the achievement of commercial milestones. In addition, Ovation agreed to certain upfront minimum purchases of CIRCUMserum™ based upon an agreed upon transfer price and yearly minimum purchases.

A copy of the press release regarding the above-described agreement is attached as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K.

On September 11, 2013, the Company announced that it had entered into an exclusive license and distribution agreement with Ovation pursuant to which Ovation will market the Company's EjectDelay™drug for the treatment of erectile dysfunction in Morocco.

Pursuant to the agreement, Ovation may pay the Company up to $18.6 million - divided into a fixed upfront license fee and subject to the achievement of regulatory and commercial milestones. In addition, Ovation agreed to certain upfront minimum purchases of EjectDelay based upon an agreed upon transfer price.

A copy of the press release regarding the above-described agreement is attached as Exhibit 99.2 and incorporated by reference into this Current Report on Form 8-K.



Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No. Description

99.1 Press Release issued September 9, 2013

99.2 Press Release issued September 11, 2013

  Add INNV to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for INNV - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.